Wyoming Senator, Mike Enzi, expressed his support for the the Food and Drug Administration User Fee Re-authorization Bill Thursday on the Senate floor.
Enzi is the top Republican on the Health, Education, Labor and Pensions (HELP) Committee, and said this bipartisian legislation was necessary.
The bill establishes a $6.4 billion fee agreement between pharmaceutical and medical companies to fund regulatory reviews of new medicines and equipment. A press release from Enzi's office said the bill will keep patients safer by regulating foreign manufacturing facilities and reducing drug costs. The bill was overwhelmingly approved in the Senate by a vote of 96-1.